Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5615_Библиотеки_им_академика_М_И_Перельмана.pdf
14 Reversible PEGylation ofNanocarriers
417
14.5.5 Immunogenicity
Despite PEG’s well-known low immunogenicity, some researchers have reported
experiencing immunological reactions. Reversible PEGylation may cause an immunological reaction when exposed to PEG repeatedly, which could eventually
decrease the medicinal agent’s effectiveness (Shiraishi and Yokoyama 2019;
Veronese 2001).
14.5.6 Scale-up Difficulties
The shift from laboratory-scale synthesis to large-scale production may pose difculties with cost-effectiveness, scalability, and reproducibility. For larger-scale
applications, the synthesis and purication techniques developed on a small scale
might need to be optimized.
14.5.7 Influence onDrug Bioavailability
PEG concentrations can affect a drug’s bioavailability. The advantages of extended
circulation times must be carefully weighed against possible changes in drug
absorption, distribution, metabolism, and excretion (ADME) patterns in reversible
PEGylation systems.
14.5.8 Cost
A major determinant of their uptake may be the expense of synthesizing and producing reversible PEGylation conjugates. One crucial factor to take into account is
the expense of synthesis, purication, and regulatory compliance in relation to the
possible advantages of better therapeutic outcomes (Tao etal. 2009).
Addressing these challenges requires interdisciplinary efforts, combining expertise in chemistry, biology, and materials science. Despite these obstacles, reversible
PEGylation holds promise for enhancing the pharmacokinetics and therapeutic outcomes of various bioactive molecules (Pomroy and Deber 1998). Ongoing research
aims to overcome these challenges and unlock the full potential of reversible
PEGylation in medical and biotechnological applications.
14.6 Conclusion
To sum up, reversible PEGylation of nanocarriers offers a viable path towards drug
delivery system optimization. Reversible PEGylation provides a careful balance
among biocompatibility and effective payload delivery by addressing the drawbacks
of irreversible PEGylation, including reduced cellular absorption and clinical
418
M. Mishra et al.
efcacy. Stimuli-responsive polymers along with cleavable linkers provide controlled dissociation of PEG chains from nanocarrier, activated by specic physiological circumstances, thereby improving targeted release at a particular site of
action. Reversible PEGylation techniques, such as pH-sensitive, temperature-triggered formulations, and enzyme-responsive, are highly versatile and can be used to
achieve more precise drug release kinetics and better therapeutic results. Expanding
up reversible PEGylation methods, maintaining stability in storage and transit, and
negotiating regulatory processes for clinical approval are still difcult tasks. In
order to fully realize the ability of reversible PEGylation to revolutionize drug delivery and ultimately result in less hazardous more efcient treatments for a variety of
disorders, it will be imperative to address these obstacles.
References
Abdelmohsen HA, Copeland NA, Hardy JG (2023) Light-responsive biomaterials for ocular drug
delivery. Drug Deliv Transl Res 13:2159–2182
Alavi SE, Bakht U, Koohi Moftakhari Esfahani M, Adelnia H, Abdollahi SH, Ebrahimi Shahmabadi
H, Raza A (2022) A PEGylated nanostructured lipid carrier for enhanced oral delivery of anti-
biotics. Pharmaceutics 14:1668
Alsawaftah NM, Awad NS, Pitt WG, Husseini GA (2022) pH-responsive nanocarriers in cancer
therapy. Polymers 14:936
Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS (2022) Nanocarrier drug deliv-
ery systems: characterization, limitations, future perspectives and implementation of articial
intelligence. Pharmaceutics 14:883
Amin M, Lammers T, Ten Hagen TL (2022) Temperature-sensitive polymers to promote heat-
triggered drug release from liposomes: towards bypassing EPR.Adv Drug Deliv Rev 114503
Arkosi M-K, Mot AC, Lupan I, Tegla MGG, Silaghi-Dumitrescu R (2023) Selective attachment of
polyethylene glycol to hemerythrin for potential use in blood substitutes. Protein J:1–9
Bista RK, Bruch RF (2008) Near-infrared spectroscopy of newly developed PEGylated lipids.
Spectrochim Acta A Mol Biomol Spectrosc 71:410–416
Böttger R, Knappe D, Hoffmann R (2016) Readily adaptable release kinetics of prodrugs using
protease-dependent reversible PEGylation. J Control Release 230:88–94
Cheng T-L, Chuang K-H, Chen B-M, Rofer SR (2012) Analytical measurement of PEGylated
molecules. Bioconjug Chem 23:881–899
Famili A, Kahook MY, Park D (2014) A combined micelle and poly (serinol hexamethylene urea)-
co-poly (N-isopropylacrylamide) reverse thermal gel as an injectable ocular drug delivery sys-
tem. Macromol Biosci 14:1719–1729
Fella C, Walker GF, Ogris M, Wagner E (2008) Amine-reactive pyridylhydrazone-based PEG
reagents for pH-reversible PEI polyplex shielding. Eur J Pharm Sci 34:309–320
Filpula D, Zhao H (2008) Releasable PEGylation of proteins with customized linkers. Adv Drug
Deliv Rev 60:29–49
Gaberc-Porekar V, Zore I, Podobnik B, Menart V (2008) Obstacles and pitfalls in the PEGylation
of therapeutic proteins. Curr Opin Drug Discov Devel 11:242
Ganji F, Abdekhodaie M (2008) Synthesis and characterization of a new thermosensitive chitosan–
PEG diblock copolymer. Carbohydr Polym 74:435–441
Ghosal S, Walker JE, Alabi CA (2021) Predictive platforms of bond cleavage and drug release
kinetics for macromolecule–drug conjugates. Annu Rev Chem Biomol Eng 12:241–261
Ghosh R, Dey J (2020) PH-responsive vesicle formation by PEGylated cholesterol derivatives:
physicochemical characterization, stability, encapsulation, and release study. Langmuir
36:5829–5838
14 Reversible PEGylation ofNanocarriers
Gupta V, Bhavanasi S, Quadir M, Singh K, Ghosh G, Vasamreddy K, Ghosh A, Siahaan TJ,
Banerjee S, Banerjee SK (2019) Protein PEGylation for cancer therapy: bench to bedside. J
Cell Commun Signal 13:319–330
Hamidi M, Azadi A, Raei P (2006) Pharmacokinetic consequences of PEGylation. Drug Deliv
13:399–409
Harris JM, Chess RB (2003) Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov
2:214–221
Higashi T, Kogo T, Sato N, Hirotsu T, Misumi S, Nakamura H, Iohara D, Onodera R, Motoyama
K, Arima H (2020) Efcient anticancer drug delivery for pancreatic cancer treatment utilizing
supramolecular polyethylene-glycosylated bromelain. ACS Appl Bio Mater 3:3005–3014
Howard MD, Jay M, Dziubla TD, Lu X (2008) PEGylation of nanocarrier drug delivery systems:
state of the art. J Biomed Nanotechnol 4:133–148
Hu F, Zhang R, Guo W, Yan T, He X, Hu F, Ren F, Ma X, Lei J, Zheng W (2020) PEGylated-PLGA
nanoparticles coated with pH-responsive tannic acid–Fe (III) complexes for reduced premature
doxorubicin release and enhanced targeting in breast cancer. Mol Pharm 18:2161–2173
Jain A, Jain SK (2008) PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug
Carrier Syst 25:403
Karimi M, Eslami M, Sahandi-Zangabad P, Mirab F, Farajisaloo N, Shafaei Z, Ghosh D,
Bozorgomid M, Dashkhaneh F, Hamblin MR (2016) pH-sensitive stimulus-responsive
nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed
Nanobiotechnol 8:696–716
Kodera Y, Matsushima A, Hiroto M, Nishimura H, Ishii A, Ueno T, Inada Y (1998) PEGylation
of proteins and bioactive substances for medical and technical applications. Prog Polym Sci
23:1233–1271
Lehner R, Hunziker P (2012) Why not just switch on the light?: light and its versatile applications
in the eld of nanomedicine. Eur J Nanomed 4:73–80
Li D, Tang G, Yao H, Zhu Y, Shi C, Fu Q, Yang F, Wang X (2022) Formulation of pH-responsive
PEGylated nanoparticles with high drug loading capacity and programmable drug release for
enhanced antibacterial activity. Bioact Mater 16:47–56
Liu Y, Liu L, Yu N, Dai L, Stella C, Chang V, Kaur S, Xu K, Wakshull E (2020) Immunoafnity
LC–MS/MS is more suitable than ELISA to quantify a PEGylated molecule in cynomolgus
monkey serum. Bioanalysis 12:1061–1069
Lv S, Song K, Yen A, Peeler DJ, Nguyen DC, Olshefsky A, Sylvestre M, Srinivasan S, Stayton
PS, Pun SH (2022) Well-dened mannosylated polymer for peptide vaccine delivery with
enhanced antitumor immunity. Adv Healthc Mater 11:2101651
Ma T, Walko M, Lepoitevin M, Janot JM, Balanzat E, Kocer A, Balme S (2018) Combining light-
gated and pH-responsive nanopore based on PEG-Spiropyran functionalization. Adv Mater
Interfaces 5:1701051
Massoumi B, Abbasian M, Jahanban-Esfahlan R, Motamedi S, Samadian H, Rezaei A,
Derakhshankhah H, Farnudiyan-Habibi A, Jaymand M (2020) PEGylated hollow pH-
responsive polymeric nanocapsules for controlled drug delivery. Polym Int 69:519–527
Mccombs JR, Owen SC (2015) Antibody drug conjugates: design and selection of linker, payload
and conjugation chemistry. AAPS J 17:339–351
Milla P, Dosio F, Cattel L (2012) PEGylation of proteins and liposomes: a powerful and exible
strategy to improve the drug delivery. Curr Drug Metab 13:105–119
Mishra P, Nayak B, Dey R (2016) PEGylation in anti-cancer therapy: an overview. Asian J Pharm
Sci 11:337–348
Moosmann A, Gerlach E, Lindner R, Böttinger H (2012) Purication of a PEGylated single chain
Fv. J Chromatogr A 1236:90–96
Motlaq VF, Knudsen KD, Nyström B (2018) Effect of PEGylation on the stability of thermore-
sponsive nanogels. J Colloid Interface Sci 524:245–255
Nesher M, Vachutinsky Y, Fridkin G, Schwarz Y, Sasson K, Fridkin M, Shechter Y, Lichtstein
D (2008) Reversible PEGylation prolongs the hypotensive effect of atrial natriuretic peptide.
Bioconjug Chem 19:342–348
419
420
Nie Y, Günther M, Gu Z, Wagner E (2011) Pyridylhydrazone-based PEGylation for pH-reversible
lipopolyplex shielding. Biomaterials 32:858–869
Ozer I, Pitoc GA, Layzer JM, Moreno A, Olson LB, Layzer KD, Hucknall AM, Sullenger BA,
Chilkoti A (2022) PEG-like brush polymer conjugate of RNA aptamer that shows reversible
anticoagulant activity and minimal immune response. Adv Mater 34:2107852
Paolino D, Accolla ML, Cilurzo F, Cristiano MC, Cosco D, Castelli F, Sarpietro MG, Fresta M,
Celia C (2017) Interaction between PEG lipid and DSPE/DSPC phospholipids: an insight of
PEGylation degree and kinetics of de-PEGylation. Colloids Surf B: Biointerfaces 155:266–275
Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y (2004) Reversible
PEGylation: a novel technology to release native interferon α2 over a prolonged time period. J
Med Chem 47:4897–4904
Pelosi C, Saitta F, Wurm FR, Fessas D, Tinè MR, Duce C (2019) Thermodynamic stability of
myoglobin-poly (ethylene glycol) bioconjugates: a calorimetric study. Thermochim Acta
671:26–31
Pomroy NC, Deber CM (1998) Solubilization of hydrophobic peptides by reversible cysteine
PEGylation. Biochem Biophys Res Commun 245:618–621
Rieger J, Grazon C, Charleux B, Alaimo D, Jérôme C (2009) Pegylated thermally responsive
block copolymer micelles and nanogels via in situ RAFT aqueous dispersion polymerization. J
Polym Sci A Polym Chem 47:2373–2390
Rustad EA, Von Hofsten S, Kumar R, Lænsman EA, Berge G, Škalko-Basnet N (2022) The pH-
responsive liposomes—the effect of PEGylation on release kinetics and cellular uptake in glio-
blastoma cells. Pharmaceutics 14:1125
Sadekar S, Ghandehari H (2012) Transepithelial transport and toxicity of PAMAM dendrimers:
implications for oral drug delivery. Adv Drug Deliv Rev 64:571–588
Shechter Y, Tsubery H, Mironchik M, Rubinstein M, Fridkin M (2005) Reversible PEGylation
of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett 579:2439–2444
Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, Fridkin M (2008)
Reversible PEGylation of insulin facilitates its prolonged action invivo. Eur J Pharm Biopharm
70:19–28
Shechter Y, Heldman E, Sasson K, Bachar T, Popov M, Fridkin M (2010) Delivery of neuropep-
tides from the periphery to the brain: studies with enkephalin. ACS Chem Neurosci 1:399–406
Shete MB, Patil TS, Deshpande AS, Saraogi G, Vasdev N, Deshpande M, Rajpoot K, Tekade RK
(2022) Current trends in theranostic nanomedicines. J Drug Deliv Sci Technol 71:103280
Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA (2022)
To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular
component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev 180:114079
Shiraishi K, Yokoyama M (2019) Toxicity and immunogenicity concerns related to PEGylated-
micelle carrier systems: a review. Sci Technol Adv Mater 20:324–336
Shiraishi Y, Shirakawa E, Tanaka K, Sakamoto H, Ichikawa S, Hirai T (2014) Spiropyran-modied
gold nanoparticles: reversible size control of aggregates by UV and visible light irradiations.
ACS Appl Mater Interfaces 6:7554–7562
Son J, Yi G, Yoo J, Park C, Koo H, Choi HS (2019) Light-responsive nanomedicine for biophotonic
imaging and targeted therapy. Adv Drug Deliv Rev 138:133–147
Stigsnaes P, Frokjaer S, Bjerregaard S, Van De Weert M, Kingshott P, Moeller EH (2007)
Characterisation and physical stability of PEGylated glucagon. Int J Pharm 330:89–98
Sun D, Ding J, Xiao C, Chen J, Zhuang X, Chen X (2015a) Drug delivery: pH-responsive revers-
ible PEGylation improves performance of antineoplastic agent (Adv. Healthcare Mater.
6/2015). Adv Healthc Mater 4:786–786
Sun D, Ding J, Xiao C, Chen J, Zhuang X, Chen X (2015b) pH-responsive reversible PEGylation
improves performance of antineoplastic agent. Adv Healthc Mater 4:844–855
Tao L, Liu J, Xu J, Davis TP (2009) Bio-reversible polyPEGylation. Chem Commun:6560–6562
Thakur S, Kesharwani P, Tekade RK, Jain NK (2015) Impact of PEGylation on biopharmaceutical
properties of dendrimers. Polymer 59:67–92
M. Mishra et al.
14 Reversible PEGylation ofNanocarriers
Thomas OS, Rebmann B, Tonn M, Schirmeister IC, Wehrle S, Becker J, Zea Jimenez GJ, Hook S,
Jäger S, Klenzendorf M (2022) Reversible shielding and immobilization of liposomes and viral
vectors by tailored antibody-ligand interactions. Small 18:2105157
Tsubery H, Mironchik M, Fridkin M, Shechter Y (2004) Prolonging the action of protein and
peptide drugs by a novel approach of reversible polyethylene glycol modication. J Biol Chem
279:38118–38124
Utatsu K, Kogo T, Taharabaru T, Onodera R, Motoyama K, Higashi T (2021) Supramolecular
polymer-based transformable material for reversible PEGylation of protein drugs. Mater Today
Bio 12:100160
Veronese FM (2001) Peptide and protein PEGylation: a review of problems and solutions.
Biomaterials 22:405–417
Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov
Today 10:1451–1458
Vllasaliu D, Fowler R, Stolnik S (2014) PEGylated nanomedicines: recent progress and remaining
concerns. Expert Opin Drug Deliv 11:139–154
Wagner E (2012) Polymers for siRNA delivery: inspired by viruses to be targeted, dynamic, and
precise. Acc Chem Res 45:1005–1013
Xing Y, Zeng B, Yang W (2022) Light responsive hydrogels for controlled drug delivery. Front
Bioeng Biotechnol 10:1075670
Yadav D, Dewangan HK (2021) PEGYLATION: an important approach for novel drug delivery
system. J Biomater Sci Polym Ed 32:266–280
Zalipsky S, Mullah N, Engbers C, Hutchins MU, Kiwan R (2007) Thiolytically cleavable dithio-
benzyl urethane-linked polymer–protein conjugates as macromolecular prodrugs: reversible
PEGylation of proteins. Bioconjug Chem 18:1869–1878
Zhang G, Jiang X (2019) Temperature responsive nanoparticles based on PEGylated polyaspar-
tamide derivatives for drug delivery. Polymers 11:316
Zhang X, Fu C, Feng L, Ji Y, Tao L, Huang Q, Li S, Wei Y (2012) PEGylation and polyPEGylation
of nanodiamond. Polymer 53:3178–3184
Zhang F, Liu M-R, Wan H-T (2014) Discussion about several potential drawbacks of PEGylated
therapeutic proteins. Biol Pharm Bull 37:335–339
Zhang X, Feng L, Dong Z, Xin X, Yang Z, Deng D, Wagner E, Liu Z, Liu X (2020) Protein-drug
conjugate programmed by pH-reversible linker for tumor hypoxia relief and enhanced cancer
combination therapy. Int J Pharm 582:119321
Zhu S, Hong M, Tang G, Qian L, Lin J, Jiang Y, Pei Y (2010) Partly PEGylated polyamidoamine
dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and
drug conjugation style. Biomaterials 31:1360–1371
Zhu Y, Chen C, Cao Z, Shen S, Li L, Li D, Wang J, Yang X (2019) On-demand PEGylation and
dePEGylation of PLA-based nanocarriers via amphiphilic mPEG-TK-Ce6 for nanoenabled
cancer chemotherapy. Theranostics 9:8312
421
Stimuli-Responsive PEGylated Nanocarriers
SamahHamedAlmurisi,
PrasanthiSriNaginderaRao,
andThiagarajanMadheswaran
Abstract
Compared to traditional medication dosage forms, nanocarrier-based delivery
systems confer several benets, including drug protection, improved bioavail-
ability, and tailored administration to disease sites. With increased availability in
the body, better drug loading values, improved intracellular transport, and supe-
rior physiological outcomes, nanocarriers are reported to improve targeted drug
delivery to cells and tissues. Stimuli-responsive nanocarriers with unique design
characteristics can adapt to exogenous and endogenous stimuli; their structure
and physicochemical properties change in response to various factors. This
results in the release of drugs at a specic target site when triggered by certain
physiological or external triggers. Numerous therapeutic and diagnostic pro-
cesses can be made substantially more effective by creating pharmaceutical
nanocarriers with multiresponsive systems. The most popular technique for giv-
ing drug nanocarriers stealthy characteristics is PEGylation. The PEG molecules
have been altered to improve their uptake by particular targets and to allow con-
trolled drug release. This chapter highlights the most recent developments in
nanocarriers with multifunctional properties and stimuli sensitivity for therapeu-
tic drug delivery applications. By delivering the drugs specically to the disease
cells, there is a pronounced enhancement in the efcacy of the treatment, improv-
ing the incidence of unwanted effects on nontarget cells, tissues, and organs.
15
S. H. Almurisi · P. S. NaginderaRao · T. Madheswaran (*)
Department of Pharmaceutical Technology, School of Pharmacy, International Medical
University, Bukit Jalil, Kuala Lumpur, Malaysia
e-mail: Thiagarajan@imu.edu.my
423
424
Keywords
S. H. Almurisi et al.
Nanocarriers · Stimuli-responsive · Drug targeting · PEGylated · Theragnostic
applications
Abbreviations
ABC Ammonium bicarbonate
AMF Magnetic eld
CAFs Cancer-associated broblasts
CAT Catalase
CPs Conductive polymers
CS Chitosan
CST Critical solution temperature
CUR Curcumin
Cys Cysteine
DOX Doxorubicin
DTT Dithiothreitol
ECs Endothelial cells
EPR Enhanced permeability and retention
Gox Glucose oxidase
GPx Glutathione peroxidase
GSH Glutathione
HA Hyaluronic acid
LCST Lower critical solution temperature
MBs Microbubbles
MC Merocyanine
MHT Magnetic hyperthermia
MMA Methyl methacrylate
MMPs Matrix metalloproteinases
MNPs Magnetic nanoparticles
MoS2 Molydenum disulde
NADPH oxidase Nicotinamide adenine dinucleotide phosphate oxidase
NBs Nanobubbles
NIR Near-infrared
NPs Nanoparticles
NR Nile red
OG Oil-soluble uorescent green
PCL Polycaprolactone
PEG Polyethylene glycol
PEGylation The process of polyethylene glycol (PEG)-based modication
of molecules for biomedical application
PEI Polyethyleneimine
pNIPAm Poly(N-isopropylacrylamide)
15 Stimuli-Responsive PEGylated Nanocarriers
425
PNIPAm Poly(N-isopropyl acrylamide
PTX Paclitaxel
RES Reticuloendothelial system
ROS Reactive oxygen species
Se Selenium
Se-Se Diselenide
SOD Superoxide dismutases
SP Spiropyran
S-S Disulde
US Ultrasound
UV Ultraviolet
γ-GCS γ-glutamyl cysteine
γ-PGA Poly-γ-glutamic acid (γ-PGA)
15.1 Introduction
New technologies incorporating advanced nanomaterials that are applicable to theranostics have evolved to address the obstacles posed by conventional dosage forms
and the adverse effects associated with pharmaceuticals. These new technologies
have dual properties, including bioimaging for diagnostic purposes and targeted
drug release for therapeutic function (Pham etal. 2020a). Engineers and researchers
have been putting more effort into designing and producing stimuli-sensitive nanomaterials with combined therapy and diagnostic functions. This is being done to
maximize the scope of nanotechnology applications for precise drug delivery and
disease diagnosis in the human tissue while maintaining a higher level of safety and
biocompatibility (Oladipo etal. 2023). These intelligent nanomaterials, utilized in
controlled drug delivery strategies, are formulated to react primarily to external
stimuli when required. Another way to implement this requirement is to trigger it
when necessary (Ahmad and Packirisamy 2020).
In contrast to conventional nanocarriers, new-generation drug nanocarriers with
stimuli-sensitive properties can recognize the environment in which bacteria are
located and the site of the infection. Furthermore, these nanocarriers respond
dynamically to specic triggers from outside factors (Bag etal. 2023). In addition
to this, they can control drug delivery patterns by preventing drug leakage before
reaching the target site to improve the delivery of loaded drugs at the target site
while simultaneously reducing the likelihood of unwanted side effects. Therefore,
nanocarriers created with nanomaterials with stimuli-sensitive properties present
distinct, improved therapeutic action and more targeted delivery. Additionally, these
nanocarriers have a superior capacity for cell penetration, which is necessary to treat
various cancers effectively (Gessner and Neundorf 2020).
In the last 10years, strategies for successfully delivering therapeutic drugs have
been developed, including polymer-based nanomaterials sensitive to stimuli. The
nanocarriers are designed to allow the release of drugs in the presence of selected
stimuli across polymer, lipid, or metal nanoparticles. These stimuli can be internal
or external or triggered by dual or multiple factors. The design of the material can
426
S. H. Almurisi et al.
be employed. The term “stimuli-responsive smart biomaterials” refers to materials
triggered in response to the local microenvironment’s pH, enzymes, physical force,
or redox stimuli to release drugs loaded into the nanocarriers. A myriad of potential
applications are associated with these biomaterials (Alves etal. 2021).
Redox potential, pH, enzymes, ions, and oxygen and glucose levels are all examples of endogenous stimuli, also known as internal or biological stimuli. These
stimuli are mostly peculiar to sick tissue and have the potential to accumulate at the
target site. They also have the potential to disrupt the structure of nanocarriers and
change the functions they perform. These stimuli-responsive drug delivery systems
observe various expression proles in response to specic cells or tissues. The
nanocarriers interact with antibodies and antigens and can detect host-guest products in a particular state to release the drug. An example of a highly specic potential trigger includes processes catalyzed by enzymes specic to particular substrates
and catalytic properties (Sheshala etal. 2022). Enzymatically catalyzed processes
possess high specicity and high catalytic properties, making them suitable as triggers for drug release. A critical challenge in drug release is an unspecic time and
nontargeted release; to overcome this, careful design and selection of stimulisensitive biomaterials is necessary. This requirement must be met to fabricate nanocarriers (Joseph etal. 2023).
In many stimuli-based drug delivery strategies, exogenous or external stimuli are
applied as chemical, biological, or physical techniques to allow the nanocarriers to
release their therapeutic drug payloads in a regulated and targeted manner, as illustrated in Fig.15.1. Exogenous triggers such as light, heat, ultrasound, and electrical
and magnetic elds can all trigger controlled drug delivery. The benets of applying
external stimuli to disrupt the structure of stimuli-sensitive nanocarriers include the
Fig. 15.1 Illustration of exogenous and endogenous stimuli-responsive systems